Systemic inflammatory response syndrome in the course of status epilepticus: 7-year, two-center observational study
•A systemic inflammatory response frequently coexists with status epilepticus, and therefore should be assessed routinely.•The assessment of SIRS among SE patients, may contribute to more effective planning of treatment and outcome prediction.•There is a link between the presence of SIRS and resista...
Saved in:
Published in | Epilepsy research Vol. 137; pp. 53 - 55 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.11.2017
|
Subjects | |
Online Access | Get full text |
ISSN | 0920-1211 1872-6844 1872-6844 |
DOI | 10.1016/j.eplepsyres.2017.09.003 |
Cover
Abstract | •A systemic inflammatory response frequently coexists with status epilepticus, and therefore should be assessed routinely.•The assessment of SIRS among SE patients, may contribute to more effective planning of treatment and outcome prediction.•There is a link between the presence of SIRS and resistance to SE treatment.
This study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was associated with drug resistance and poor outcome in status epilepticus (SE) patients.
We conducted a prospective review of patients consecutively admitted to two territory centers over a 7-year period. SIRS was considered present if the necessary criteria persisted for 12h. Other potential outcome predictors in a cohort of patients with SE were also collected. The primary outcome was defined as mortality during 30 days of observation, and the secondary outcome was defined as refractory SE. Logistic regression was used to determine independent predictors.
Of 127 subjects, 85 patients met the inclusion criteria. In the entire population, 43% developed SIRS at SE onset and, among them, 16% had SIRS attributed to SE alone. Subjects with refractory SE accounted for 39%, and the mortality rate for the entire population was 35%. SIRS was independently associated with drug resistance (OR 3.93, 95% CI: 1.57–9.9) and death (OR 6.76, 95% CI: 1.33–34.32).
We observed that approximately half of the patients with SE developed SIRS, and that SIRS is the independent risk factor for drug resistance and death. We also observed that SIRS was a secondary event for SE itself. |
---|---|
AbstractList | This study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was associated with drug resistance and poor outcome in status epilepticus (SE) patients.
We conducted a prospective review of patients consecutively admitted to two territory centers over a 7-year period. SIRS was considered present if the necessary criteria persisted for 12h. Other potential outcome predictors in a cohort of patients with SE were also collected. The primary outcome was defined as mortality during 30 days of observation, and the secondary outcome was defined as refractory SE. Logistic regression was used to determine independent predictors.
Of 127 subjects, 85 patients met the inclusion criteria. In the entire population, 43% developed SIRS at SE onset and, among them, 16% had SIRS attributed to SE alone. Subjects with refractory SE accounted for 39%, and the mortality rate for the entire population was 35%. SIRS was independently associated with drug resistance (OR 3.93, 95% CI: 1.57-9.9) and death (OR 6.76, 95% CI: 1.33-34.32).
We observed that approximately half of the patients with SE developed SIRS, and that SIRS is the independent risk factor for drug resistance and death. We also observed that SIRS was a secondary event for SE itself. •A systemic inflammatory response frequently coexists with status epilepticus, and therefore should be assessed routinely.•The assessment of SIRS among SE patients, may contribute to more effective planning of treatment and outcome prediction.•There is a link between the presence of SIRS and resistance to SE treatment. This study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was associated with drug resistance and poor outcome in status epilepticus (SE) patients. We conducted a prospective review of patients consecutively admitted to two territory centers over a 7-year period. SIRS was considered present if the necessary criteria persisted for 12h. Other potential outcome predictors in a cohort of patients with SE were also collected. The primary outcome was defined as mortality during 30 days of observation, and the secondary outcome was defined as refractory SE. Logistic regression was used to determine independent predictors. Of 127 subjects, 85 patients met the inclusion criteria. In the entire population, 43% developed SIRS at SE onset and, among them, 16% had SIRS attributed to SE alone. Subjects with refractory SE accounted for 39%, and the mortality rate for the entire population was 35%. SIRS was independently associated with drug resistance (OR 3.93, 95% CI: 1.57–9.9) and death (OR 6.76, 95% CI: 1.33–34.32). We observed that approximately half of the patients with SE developed SIRS, and that SIRS is the independent risk factor for drug resistance and death. We also observed that SIRS was a secondary event for SE itself. This study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was associated with drug resistance and poor outcome in status epilepticus (SE) patients.OBJECTIVESThis study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was associated with drug resistance and poor outcome in status epilepticus (SE) patients.We conducted a prospective review of patients consecutively admitted to two territory centers over a 7-year period. SIRS was considered present if the necessary criteria persisted for 12h. Other potential outcome predictors in a cohort of patients with SE were also collected. The primary outcome was defined as mortality during 30 days of observation, and the secondary outcome was defined as refractory SE. Logistic regression was used to determine independent predictors.METHODSWe conducted a prospective review of patients consecutively admitted to two territory centers over a 7-year period. SIRS was considered present if the necessary criteria persisted for 12h. Other potential outcome predictors in a cohort of patients with SE were also collected. The primary outcome was defined as mortality during 30 days of observation, and the secondary outcome was defined as refractory SE. Logistic regression was used to determine independent predictors.Of 127 subjects, 85 patients met the inclusion criteria. In the entire population, 43% developed SIRS at SE onset and, among them, 16% had SIRS attributed to SE alone. Subjects with refractory SE accounted for 39%, and the mortality rate for the entire population was 35%. SIRS was independently associated with drug resistance (OR 3.93, 95% CI: 1.57-9.9) and death (OR 6.76, 95% CI: 1.33-34.32).RESULTSOf 127 subjects, 85 patients met the inclusion criteria. In the entire population, 43% developed SIRS at SE onset and, among them, 16% had SIRS attributed to SE alone. Subjects with refractory SE accounted for 39%, and the mortality rate for the entire population was 35%. SIRS was independently associated with drug resistance (OR 3.93, 95% CI: 1.57-9.9) and death (OR 6.76, 95% CI: 1.33-34.32).We observed that approximately half of the patients with SE developed SIRS, and that SIRS is the independent risk factor for drug resistance and death. We also observed that SIRS was a secondary event for SE itself.CONCLUSIONSWe observed that approximately half of the patients with SE developed SIRS, and that SIRS is the independent risk factor for drug resistance and death. We also observed that SIRS was a secondary event for SE itself. |
Author | Bielecki, Dariusz Rejdak, Konrad Godek, Magdalena Balicka-Adamik, Luiza Szklener, Sebastian Rejdak, Robert Korchut, Agnieszka |
Author_xml | – sequence: 1 givenname: Sebastian surname: Szklener fullname: Szklener, Sebastian organization: Department of Neurology, Medical University of Lublin, Poland – sequence: 2 givenname: Agnieszka surname: Korchut fullname: Korchut, Agnieszka organization: Department of Neurology, Medical University of Lublin, Poland – sequence: 3 givenname: Magdalena surname: Godek fullname: Godek, Magdalena organization: Department of Neurology, Medical University of Lublin, Poland – sequence: 4 givenname: Luiza surname: Balicka-Adamik fullname: Balicka-Adamik, Luiza organization: Department of Neurology, Public Hospital in Jarosław, Poland – sequence: 5 givenname: Dariusz surname: Bielecki fullname: Bielecki, Dariusz organization: Department of Neurology, Public Hospital in Jarosław, Poland – sequence: 6 givenname: Robert surname: Rejdak fullname: Rejdak, Robert organization: Department of General Ophthalmology, Medical University of Lublin, Poland – sequence: 7 givenname: Konrad surname: Rejdak fullname: Rejdak, Konrad email: konrad.rejdak@umlub.pl organization: Department of Neurology, Medical University of Lublin, Poland |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28938136$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkUtv1TAQhS1URG8LfwF5yYKk40ceZoGACgpSJRbA2nKcifAliYPtFOXf48stIHV1N2NpfM6n0TkX5Gz2MxJCGZQMWH21L3EZcYlbwFhyYE0JqgQQj8iOtQ0v6lbKM7IDxaFgnLFzchHjHgAakPIJOeetEi0T9Y7EL1tMODlL3TyMZppM8mGjmbv4OSKN29wHP2H-puk7UuvXkNd-oDGZtEaKi8uXJGfX-Io2xYYmvKTply8szgkD9V3EcGeS87MZs2ntt6fk8WDGiM_u30vy7cP7r9cfi9vPN5-u394WVqomHSYfACqLXVtbpiojLBeqVxJQqK4V0kiA2iissBKqBsbagQ2qR9Oojlfikrw4cpfgf64Yk55ctDiOZka_Rs2U5I2oK8mz9Pm9dO0m7PUS3GTCpv8GlQXtUWCDjzHg8E_CQB860Xv9vxN96ESD0rmTbH39wGpd-hNICsaNpwDeHQGYw7pzGHS0DmeLvQtok-69OwXy5gHEjm521ow_cDsN8Rtoy8e6 |
CitedBy_id | crossref_primary_10_1212_WNL_0000000000206838 crossref_primary_10_1097_WNP_0000000000000753 crossref_primary_10_1016_j_yebeh_2024_110232 crossref_primary_10_1186_s13578_022_00949_6 crossref_primary_10_2147_DDDT_S249162 crossref_primary_10_2174_1570159X21666221117152249 crossref_primary_10_1111_jcmm_14676 crossref_primary_10_1016_j_seizure_2020_08_021 crossref_primary_10_1111_epi_14524 crossref_primary_10_1111_epi_16842 crossref_primary_10_3389_fnmol_2018_00341 crossref_primary_10_1016_j_yebeh_2022_108649 crossref_primary_10_1016_j_seizure_2023_02_001 crossref_primary_10_1007_s12028_021_01256_7 crossref_primary_10_1248_bpb_b21_00574 crossref_primary_10_32587_jnic_2022_00514 crossref_primary_10_1038_s41598_024_72142_3 crossref_primary_10_3389_fneur_2022_964923 |
Cites_doi | 10.1016/j.yebeh.2015.04.047 10.1016/j.yebeh.2016.09.036 10.1002/ana.24166 10.1186/s13054-015-1072-9 10.1111/epi.12271 10.1136/jnnp.2005.080887 10.1016/j.seizure.2017.01.004 10.1007/s12028-016-0255-9 |
ContentType | Journal Article |
Copyright | 2017 Copyright © 2017. Published by Elsevier B.V. |
Copyright_xml | – notice: 2017 – notice: Copyright © 2017. Published by Elsevier B.V. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.eplepsyres.2017.09.003 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1872-6844 |
EndPage | 55 |
ExternalDocumentID | 28938136 10_1016_j_eplepsyres_2017_09_003 S0920121117301353 |
Genre | Multicenter Study Journal Article Observational Study |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABJNI ABMAC ABMZM ABTEW ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRLJ AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDW HMK HMO HMQ HVGLF HZ~ IHE J1W K-O KOM L7B LX8 M29 M2V M41 MO0 MOBAO N9A O-L O9- OAUVE OP~ OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SEL SES SEW SNS SPCBC SSH SSN SSZ T5K UNMZH WUQ Z5R ~G- AACTN AADPK AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW EFLBG LCYCR RIG AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 ACLOT ~HD |
ID | FETCH-LOGICAL-c497t-c492f005ceb86c195a3c239d940e39b834a4006a9e5e53960118f1f9dea79b253 |
IEDL.DBID | .~1 |
ISSN | 0920-1211 1872-6844 |
IngestDate | Sun Sep 28 12:30:46 EDT 2025 Wed Feb 19 02:40:55 EST 2025 Tue Jul 01 03:29:45 EDT 2025 Thu Apr 24 22:51:37 EDT 2025 Fri Feb 23 02:30:55 EST 2024 Tue Aug 26 16:32:30 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | Copyright © 2017. Published by Elsevier B.V. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c497t-c492f005ceb86c195a3c239d940e39b834a4006a9e5e53960118f1f9dea79b253 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
PMID | 28938136 |
PQID | 1942736542 |
PQPubID | 23479 |
PageCount | 3 |
ParticipantIDs | proquest_miscellaneous_1942736542 pubmed_primary_28938136 crossref_primary_10_1016_j_eplepsyres_2017_09_003 crossref_citationtrail_10_1016_j_eplepsyres_2017_09_003 elsevier_sciencedirect_doi_10_1016_j_eplepsyres_2017_09_003 elsevier_clinicalkey_doi_10_1016_j_eplepsyres_2017_09_003 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2017 2017-11-00 20171101 |
PublicationDateYYYYMMDD | 2017-11-01 |
PublicationDate_xml | – month: 11 year: 2017 text: November 2017 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Epilepsy research |
PublicationTitleAlternate | Epilepsy Res |
PublicationYear | 2017 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Gorter, van Vliet, Aronica (bib0020) 2015; 49 Janigro, Iffland, Marchi, Granata (bib0025) 2013; 54 Claassen, Albers, Schmidt, De Marchis, Pugin, Falo, Mayer, Cremers, Agarwal, Elkind, Connolly, Dukic, Hripcsak, Badjatia (bib0010) 2014; 75 Sutter, Valença, Tschudin-Sutter, Rüegg, Marsch (bib0040) 2015; 9 Pacha, Orellana, Silva, Ernst, Pantiu, Quiroga Narvaez, Reisin, Martinez (bib0030) 2016; 64 Boehme, Hays, Kicielinski, Arora, Kapoor, Lyerly, Gadpaille, Shiue, Albright, Miller, Elkind, Harrigan (bib0005) 2016; 25 Rossetti, Hurwitz, Logroscino, Bromfield (bib0035) 2006; 77 Giovannini, Monti, Tondelli, Marudi, Valzania, Leitinger, Trinka, Meletti (bib0015) 2017; 46 Rossetti (10.1016/j.eplepsyres.2017.09.003_bib0035) 2006; 77 Claassen (10.1016/j.eplepsyres.2017.09.003_bib0010) 2014; 75 Gorter (10.1016/j.eplepsyres.2017.09.003_bib0020) 2015; 49 Giovannini (10.1016/j.eplepsyres.2017.09.003_bib0015) 2017; 46 Sutter (10.1016/j.eplepsyres.2017.09.003_bib0040) 2015; 9 Boehme (10.1016/j.eplepsyres.2017.09.003_bib0005) 2016; 25 Pacha (10.1016/j.eplepsyres.2017.09.003_bib0030) 2016; 64 Janigro (10.1016/j.eplepsyres.2017.09.003_bib0025) 2013; 54 |
References_xml | – volume: 49 start-page: 13 year: 2015 end-page: 16 ident: bib0020 article-title: Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis publication-title: Epilepsy Behav. – volume: 46 start-page: 31 year: 2017 end-page: 37 ident: bib0015 article-title: Mortality, morbidity and refractoriness prediction in status epilepticus: comparison of STESS and EMSE scores publication-title: Seizure – volume: 77 start-page: 611 year: 2006 end-page: 615 ident: bib0035 article-title: Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation publication-title: J. Neurol. Neurosurg. Psychiatry – volume: 75 start-page: 771 year: 2014 end-page: 781 ident: bib0010 article-title: Nonconvulsive seizures in subarachnoid hemorrhage link inflammation and outcome publication-title: Ann. Neurol. – volume: 25 start-page: 133 year: 2016 end-page: 140 ident: bib0005 article-title: Systemic inflammatory response syndrome and outcomes in intracerebral hemorrhage publication-title: Neurocrit. Care – volume: 9 start-page: 361 year: 2015 ident: bib0040 article-title: Procalcitonin and mortality in status epilepticus: an observational cohort study publication-title: Crit. Care – volume: 54 start-page: 30 year: 2013 end-page: 32 ident: bib0025 article-title: A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches publication-title: Epilepsia – volume: 64 start-page: 140 year: 2016 end-page: 142 ident: bib0030 article-title: Role of EMSE and STESS scores in the outcome evaluation of status epilepticus publication-title: Epilepsy Behav. – volume: 49 start-page: 13 year: 2015 ident: 10.1016/j.eplepsyres.2017.09.003_bib0020 article-title: Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis publication-title: Epilepsy Behav. doi: 10.1016/j.yebeh.2015.04.047 – volume: 64 start-page: 140 year: 2016 ident: 10.1016/j.eplepsyres.2017.09.003_bib0030 article-title: Role of EMSE and STESS scores in the outcome evaluation of status epilepticus publication-title: Epilepsy Behav. doi: 10.1016/j.yebeh.2016.09.036 – volume: 75 start-page: 771 year: 2014 ident: 10.1016/j.eplepsyres.2017.09.003_bib0010 article-title: Nonconvulsive seizures in subarachnoid hemorrhage link inflammation and outcome publication-title: Ann. Neurol. doi: 10.1002/ana.24166 – volume: 9 start-page: 361 issue: 19 year: 2015 ident: 10.1016/j.eplepsyres.2017.09.003_bib0040 article-title: Procalcitonin and mortality in status epilepticus: an observational cohort study publication-title: Crit. Care doi: 10.1186/s13054-015-1072-9 – volume: 54 start-page: 30 year: 2013 ident: 10.1016/j.eplepsyres.2017.09.003_bib0025 article-title: A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches publication-title: Epilepsia doi: 10.1111/epi.12271 – volume: 77 start-page: 611 year: 2006 ident: 10.1016/j.eplepsyres.2017.09.003_bib0035 article-title: Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation publication-title: J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp.2005.080887 – volume: 46 start-page: 31 year: 2017 ident: 10.1016/j.eplepsyres.2017.09.003_bib0015 article-title: Mortality, morbidity and refractoriness prediction in status epilepticus: comparison of STESS and EMSE scores publication-title: Seizure doi: 10.1016/j.seizure.2017.01.004 – volume: 25 start-page: 133 year: 2016 ident: 10.1016/j.eplepsyres.2017.09.003_bib0005 article-title: Systemic inflammatory response syndrome and outcomes in intracerebral hemorrhage publication-title: Neurocrit. Care doi: 10.1007/s12028-016-0255-9 |
SSID | ssj0007044 |
Score | 2.3006055 |
Snippet | •A systemic inflammatory response frequently coexists with status epilepticus, and therefore should be assessed routinely.•The assessment of SIRS among SE... This study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 53 |
SubjectTerms | Aged Drug Resistance Female Follow-Up Studies Humans Logistic Models Male Middle Aged Prospective Studies Status Epilepticus - complications Status Epilepticus - drug therapy Status Epilepticus - mortality Status Epilepticus - physiopathology Systemic Inflammatory Response Syndrome - complications Systemic Inflammatory Response Syndrome - drug therapy Systemic Inflammatory Response Syndrome - mortality Systemic Inflammatory Response Syndrome - physiopathology |
Title | Systemic inflammatory response syndrome in the course of status epilepticus: 7-year, two-center observational study |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0920121117301353 https://dx.doi.org/10.1016/j.eplepsyres.2017.09.003 https://www.ncbi.nlm.nih.gov/pubmed/28938136 https://www.proquest.com/docview/1942736542 |
Volume | 137 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1872-6844 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0007044 issn: 0920-1211 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier ScienceDirect customDbUrl: eissn: 1872-6844 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0007044 issn: 0920-1211 databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] - NZ customDbUrl: eissn: 1872-6844 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0007044 issn: 0920-1211 databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection 2013 customDbUrl: eissn: 1872-6844 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0007044 issn: 0920-1211 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1872-6844 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0007044 issn: 0920-1211 databaseCode: AKRWK dateStart: 19870101 isFulltext: true providerName: Library Specific Holdings |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9swEBalg9GX0Xbrlq4rGow-xYtt2Za1PZWykm20FNZC34SknCGji02cMPKyv313kp0wSiGwF4N_HJal0-nO-u47xj4UIApZmQSVt4QoM7KKytzYKBGFMy62k8pXnru6LsZ32bf7_H6HXfS5MASr7Gx_sOneWndXRl1vjprpdPQjVqknKEtISUVOjJ_E_oU6_fHPBuYhY1_QlR6O6OkOzRMwXtA8QNOuMLAlkJf0jKd9-azHS9RTLqhfii732YvOh-TnoZkHbAdmh-z5VbdLfsjObgIf9WrIbzfpVe2Qn_GbDVP16iVrA1_51HHUM1SNX37Lnc8DbhZ4T2eAtzk6itzVBPngdcUpD2nZcmjQqDTE39F-4jJa4bQZ8sXvOiLMJ8x5bdc_fbHBnsr2Fbu7_HJ7MY66KgyRy5Rc0DGtcK46sGXhEpUb4VKhJiqLQShbisygHSiMghxygQERhixVUqkJGKlsmosjtjurZ_CGceVUatDlxBURbYUlV0VJ63LrDKROlgMm-47XrqMop0oZD7rHov3UmyHTNGQ6VkRvOmDJWrIJNB1byKh-bHWfhoqGU-NasoXs57XsP-q6pfT7XpU0zmbaojEzqJetTlSG_iQVERuw10HH1t-DoTG6V6I4_q93v2V7dBbSKU_Y7mK-hHfoVy3sqZ84p-zZ-dfv4-u_SJMmgQ |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9swED66FLa9jK7burT7ocHoU0xsy7Ks7qmUlXRtQmEp9E1IigwZXWzihJL_fidbdihjENiLHywflqXTpzvr7juAr6mlKc9VhMqb2SBRPA8ypnQQ0dQoE-pZXleeG0_S0V3y457d78FFmwvjwio99jeYXqO1vzP0ozks5_Phz1DENUFZ5JSUMvoM9hOGmNyD_fOr69GkA2Qe1jVd3fOBE_ABPU2Yly0fbFlt0Ld1cV68Jj1tK2j9vUv9ywqtd6PLA3jlzUhy3vT0NezZxSE8H_uD8kM4vW0oqTcDMt1mWFUDckput2TVmzdQNZTlc0NQ1VA7ften7mTZhM5a0jIaYDNBW5GYwkV9kCInLhVpXRFbIq6UjsKjOiM82ODKGZDVYxG4sE-7JIXu_vtih2s227dwd_l9ejEKfCGGwCSCr9w1znG5Gquz1ESCKWpiKmYiCS0VOqOJQihIlbDMMoo-EXoteZSLmVVc6JjRd9BbFAv7HogwIlZodeKmiHChnbUiuDZMG2Vjw7M-8HbgpfEs5a5YxoNsw9F-ye2USTdlMhSO4bQPUSdZNkwdO8iIdm5lm4mK2ClxO9lB9lsn-0Rjd5T-0qqSxAXtTmnUwhbrSkYiQZPS1RHrw1GjY933oHeMFhZNj__r3Z_hxWg6vpE3V5PrE3jpWprsyg_QWy3X9iOaWSv9yS-jPyvYKSw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systemic+inflammatory+response+syndrome+in+the+course+of+status+epilepticus%3A+7-year%2C+two-center+observational+study&rft.jtitle=Epilepsy+research&rft.au=Szklener%2C+Sebastian&rft.au=Korchut%2C+Agnieszka&rft.au=Godek%2C+Magdalena&rft.au=Balicka-Adamik%2C+Luiza&rft.date=2017-11-01&rft.pub=Elsevier+B.V&rft.issn=0920-1211&rft.volume=137&rft.spage=53&rft.epage=55&rft_id=info:doi/10.1016%2Fj.eplepsyres.2017.09.003&rft.externalDocID=S0920121117301353 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0920-1211&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0920-1211&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0920-1211&client=summon |